EUVIMEDEUVIMED entdecken
Crossref

Risk of Cardiovascular Implantable Electronic Device Infection in Patients With Cardiac Sarcoidosis

Chukwuka Ibecheozor iD, Jonathon Mitchell, Chloe Duvall, Anjali Wagle, Maryam M Sani, Nisha A Gilotra, Jonathan Chrispin

Journal of Cardiovascular Electrophysiology · 2026

DOI: 10.1111/jce.70301 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cardiovascular Electrophysiology, 2026. Verfasst von Chukwuka Ibecheozor und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Sarcoidosis, Defibrillators, Implantable, Cardiomyopathies, Immunosuppressive Agents. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Ann Theodore Foundation Breakthrough Sarcoidosis Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immunosuppressive therapy plays a key role in managing cardiac sarcoidosis (CS). The decision to implant a cardiovascular implantable electronic device (CIED) is frequently made alongside the initiation of immunosuppression. However, it remains unclear whether being on immunosuppressive therapy at the time of CIED implantation increases the risk of infection. As both interventions can be lifesaving, it is important to determine whether adjustments to immunosuppressive regimens are necessary to mitigate infection risk.

Objective

To assess the correlation between CIED‐related infections and Immunosuppression in patients with cardiac sarcoidosis at a tertiary care center.

Methods

We conducted a retrospective review of patients with biopsy‐confirmed CS who received a CIED and were followed at Johns Hopkins Hospital. Data collected included CIED type, number of procedures and leads, use of an antibiotic envelope, and immunosuppressive therapy at the time of each procedure. The primary outcome was the occurrence of a CIED pocket infection or bloodstream infection (BSI).

Results

A total of 175 patients were included, with a mean age of 60.1 years (SD ± 11.4); 63.4% were male, 53.1% were White, and 41.1% Black. The majority received implantable cardioverter‐defibrillators (ICDs) (162/175, 92.5%). The average follow‐up duration was 8.6 years. At the time of implantation, 70 patients were on immunosuppressive therapy: 36 on corticosteroids alone, 8 on steroid‐sparing agents, and 26 on combination therapy. During the follow‐up period, 12 patients developed BSIs. Of these, 5 were on immunosuppression at the time of implantation. All infections were treated with antibiotics; 9 patients underwent device extraction. There was no significant difference in infection rates between those on immunosuppression at implantation and those who were not (5/70 vs. 7/105; p = 0.90). There was no significant difference in management between both groups. Two patients also developed pocket infections, both following multiple prior CIED procedures. One case involved a S. aureus infection 4 years after a revision performed while on immunosuppression. The other involved a Propionibacterium acnes infection 4 months after a revision performed off immunosuppression.

Conclusion

In this cohort of patients with cardiac sarcoidosis undergoing CIED implantation, immunosuppressive therapy at the time of implantation was not associated with an increased risk of device‐related infection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SarcoidosisDefibrillators, ImplantableCardiomyopathiesImmunosuppressive AgentsProsthesis-Related InfectionsPacemaker, ArtificialElectric CountershockHumansRetrospective StudiesRisk FactorsMaleFemaleMiddle AgedAgedTime FactorsRisk AssessmentTreatment OutcomeImmunocompromised HostAnti-Bacterial Agents

Stichwörter der Autor:innen

cardiac implantable electronic devicescardiac sarcoidosisimmunosuppressioninfection

Substanzen

Immunosuppressive AgentsAnti-Bacterial Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
  • Department of Medicine, New York Presbyterian Hospital-Cornell Campus, New York, New York, USA.
  • Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Department of Medicine, Yale New Haven Hospital, New Haven, Connecticut, USA.

ORCID-Profile: Chukwuka Ibecheozor

Förderung

  • Ann Theodore Foundation Breakthrough Sarcoidosis Initiative

Zitieren

APA

Ibecheozor, C., Mitchell, J., Duvall, C., Wagle, A., Sani, M. M., Gilotra, N. A., & Chrispin, J. (2026). Risk of Cardiovascular Implantable Electronic Device Infection in Patients With Cardiac Sarcoidosis. Journal of Cardiovascular Electrophysiology. https://doi.org/10.1111/jce.70301

Vancouver

Ibecheozor C, Mitchell J, Duvall C, Wagle A, Sani MM, Gilotra NA, et al. Risk of Cardiovascular Implantable Electronic Device Infection in Patients With Cardiac Sarcoidosis. Journal of Cardiovascular Electrophysiology. 2026. doi:10.1111/jce.70301

BibTeX
@article{Ibecheozor2026,
  author = {Ibecheozor, Chukwuka and Mitchell, Jonathon and Duvall, Chloe and Wagle, Anjali and Sani, Maryam M and Gilotra, Nisha A and Chrispin, Jonathan},
  title = {Risk of Cardiovascular Implantable Electronic Device Infection in Patients With Cardiac Sarcoidosis},
  journal = {Journal of Cardiovascular Electrophysiology},
  year = {2026},
  doi = {10.1111/jce.70301}
}
Kostenlos starten →